Highlights Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Market Closed - Nasdaq Other stock markets 21:00:00 18/06/2024 BST			5-day change	1st Jan Change
2.75 ^USD	0.00%		-7.72%	+11.34%

06-11	Transcript : Ventyx Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
06-06	Oppenheimer Adjusts Ventyx Biosciences Price Target to $10 From $12, Maintains Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results	06-05	MT
Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers	06-05	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
North American Morning Briefing : Stock Futures -2-	03-13	DJ
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event	03-11	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis	11-06	CI
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative Colitis	09/10/23	CI
Ventyx Biosciences Q2 Net Loss Widens	10/08/23	MT
Ventyx Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 Inhibitor	14/06/23	CI
Ventyx Biosciences Q1 Loss Widens	11/05/23	MT
Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Ventyx Biosciences, Inc. acquired Zomagen Biosciences Ltd.	13/04/23	CI
Ventyx Biosciences, Inc Announces Dosing of the First Patient in the Phase 2 Serenity Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis	01/12/22	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
Sector Update: Health Care Stocks Finding Modest Buying Support Late, but Still Unable to Reach Positive Ground	16/09/22	MT
Sector Update: Health Care Stocks Declining in Friday Trading	16/09/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Highlights

Filters